Dupixent® (dupilumab) recommended for eu approval by the chmp to treat eosinophilic esophagitis (eoe) in children as young as 1 year old

Recommendation based on a phase 3 trial showing a significantly greater proportion of children on dupixent achieved histological remission compared to placebo, consistent with improvements seen in adults and adolescents
REGN Ratings Summary
REGN Quant Ranking